{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-031482","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.056879+00:00","generated_at":"2026-06-04T19:46:21.394861+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Enliven reports 2023 net loss $71.6M; cash $253M; ELVN-001 data due Q2 2024","bullets":["Net loss of $71.6M for full year 2023, up from $37.7M in 2022; R&D spend $64.6M.","Cash, cash equivalents and marketable securities $253.1M; expected runway into early 2026.","Phase 1a ELVN-001 proof-of-concept data expected Q2 2024 (n>20 patients at efficacious dose).","ELVN-002 IND cleared for combination with trastuzumab in HER2+ cancers; first patient dosing by mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-031482","json":"https://secwatch.observer/filing/0000950170-24-031482.json","markdown":"https://secwatch.observer/filing/0000950170-24-031482.md","text":"https://secwatch.observer/filing/0000950170-24-031482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000095017024031482/0000950170-24-031482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000095017024031482/elvn-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:46:21.394861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"511b0ee0ba0b5aafff5bc2b061daf1293e4e1723","claim":"Enliven Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net loss of $19.4 million for the fourth quarter of 2023.","evidence_excerpt":"Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the fourth quarter and full year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672619/000095017024031482/0000950170-24-031482-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"net loss of $19.4 million for the fourth quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}